Credits Available: 4.5 AMA PRA Category 1 Credit™ & 4.5 MOC Points

Description: This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, to learn and share best practices that will improve outcomes for patients with advanced and metastatic urothelial carcinoma. Advanced and metastatic urothelial carcinoma (a/mUC) of the bladder comprises a small subset of all urothelial tumors but accounts for the majority of the rapid mortality associated with this disease. Over the last decade, accelerating basic science research has enabled a deeper understanding of the molecular biology of urothelial tumors, leading to the development of novel treatment strategies. Immune checkpoint inhibitors (ICIs) have demonstrated encouraging results in the first-line and second-line treatment of mUC as well as in treatment-naïve cisplatin-ineligible patients with some durable responses and a favorable toxicity profile when compared to further chemotherapy. More recently, a new ICI/antibody-drug conjugate (ADC) combination has been approved. Given these changes, educational gaps exist for clinicians treating patients with advanced or metastatic UC in the areas of (1) determining cisplatin/platinum eligibility, (2) use of immuno-oncologic (IO) agents and IO/ADC combinations, and (3) managing adverse events associated with these treatments. This social learning experience will address these gaps and provide the opportunity to collaborate.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Assistant, Pharmacist
Target Specialties: Oncology, Hematology/Oncology
Dr. Karine Tawagi practices in the Division of Hematology & Oncology at UI Health. Dr. Tawagi's clinical focus is the treatment of genitourinary cancers including but not limited to bladder, kidney, testicular and prostate cancer. Her research interests focus on clinical trials in genitourinary cancers, in addition to the use of immunotherapy in cancer treatment while developing strategies to diagnose, treat, and minimize side effects related to immunotherapy. Dr. Tawagi is dedicated to providing the best, most up-to-date treatment for all her patients, with consideration of each patient's specific goals and preferences. During clinic visits, all potential treatment options are discussed carefully with other members of the cancer care team, and with patients and their families. In addition to direct patient care and research, Dr. Tawagi also has a strong passion for medical education to help improve current gaps in healthcare.